The clinical efficacy of alprazolam has been evaluated in both anxiety states and depressive disorders. In anxiety neurosis, studies have been conducted vs placebo and/or other benzodiazepine tranquilizers. Reports, to date, with regard to panic/phobia disorders have been limited to open‐label studies and a single report from a placebo‐ controlled study. In depression, both open‐label and double‐blind studies (vs tricyclic antidepressants) have been published.
DOI: 10.1111/j.1365-2125.1985.tb02743.x
View this article